Inspection Readiness Lead

Senior Director, Medical Affairs

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

ADAXION Therapeutics

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AS2 Bio Inc

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Adiso Therapeutics

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aera Therapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Akttyva Therapeutics

Alamar Biosciences

Aldebaran Therapeutics

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Larimar Therapeutics is developing therapies for rare genetic diseases that currently have no effective treatments. Genetic mutations can cause cells to have low levels of a protein which leads to disease. Using their proprietary protein replacement therapy platform, Larimar is developing disease modifying therapies that deliver missing proteins directly to cells that need it. Larimar’s lead candidate, CTI-1601, is currently being evaluated in Phase 1 clinical trials for Friedreich’s ataxia. Friedreich’s ataxia patients have low levels of endogenous Frataxin, a protein that functions in the mitochondria. CTI-1601 is a fusion protein that contains Frataxin and crosses the cell membrane into the cytoplasm. CTI-0601 also contains information to enter the mitochondria, where it is needed.

<p>Larimar Therapeutics is developing therapies for rare genetic diseases that currently have no effective treatments. Genetic mutations can cause cells to have low levels of a protein which leads to disease. Using their proprietary protein replacement therapy platform, Larimar is developing disease modifying therapies that deliver missing proteins directly to cells that need it. Larimar’s lead candidate, CTI-1601, is currently being evaluated in Phase 1 clinical trials for Friedreich’s ataxia. Friedreich’s ataxia patients have low levels of endogenous Frataxin, a protein that functions in the mitochondria. CTI-1601 is a fusion protein that contains Frataxin and crosses the cell membrane into the cytoplasm. CTI-0601 also contains information to enter the mitochondria, where it is needed.</p>


Find a biotech startup job.